Roland Griffiths
Professor of Neuroscience and Psychiatry
Data updated
Research Footprint
Roland Griffiths appears in 69 tracked papers (2006–2026) and 1 clinical trial, most studied alongside Psilocybin, LSD and Ayahuasca, across Anxiety Disorders, Depressive Disorders and Substance Use Disorders (SUD).
Most-cited paper: Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer (2144 citations).
Frequent co-authors: Matthew Johnson, Frederick Barrett and Alan Davis.
Publication Landscape
How the 69 papers Blossom tracks for Roland Griffiths line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Roland Griffiths's publishing grown?
SourcedTracked papers by publication year; 6 earlier papers published before 2012. Click a year for the running total.
Don't read as total output: only the 69 of 69 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Roland Griffiths publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Roland Griffiths publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Roland Griffiths (1946–2023) was a titan of psychopharmacology at Johns Hopkins University. He is credited with initiating the modern era of psychedelic research with his landmark 2006 study on psilocybin and mystical experiences. His career spanned over 50 years, during which he founded the Johns Hopkins Center for Psychedelic and Consciousness Research and led groundbreaking trials for cancer-related distress and smoking cessation.
Key Impact
Seminal figure in the modern 'psychedelic renaissance' and founding director of the Johns Hopkins Center for Psychedelic and Consciousness Research.
Collaboration Network
43 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Roland Griffiths's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Roland Griffiths is associated with.
Johns Hopkins University
academicThe Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
View stakeholder →Johns Hopkins Center for Psychedelic and Consciousness Research
The Johns Hopkins Center for Psychedelic and Consciousness Research sits within the School of Medicine in Baltimore and is one of the most established programmes of its kind. It opened in 2019 with roughly 17 million dollars in private donations, and was founded under Roland Griffiths, whose earlier psilocybin work helped revive modern clinical study of these compounds. Frederick Barrett took over as director in 2023. The centre studies how classic psychedelics such as psilocybin affect brain function, cognition and mood, and runs trials in conditions including depression, tobacco dependence and anorexia. Its scientists combine clinical trials with neuroimaging and questionnaire measures of the psychedelic experience, and much of the field's shared vocabulary traces back to work done here.
View stakeholder →